Pleiotrophin expression and role in physiological angiogenesis in vivo: Potential involvement of nucleolin

Vascular Cell

Volumn 4, Issue , 2012, Pages

  Koutsioumpa, Marina ^a   Drosou, Georgia ^a   Mikelis, Constantinos ^a,c   Theochari, Katerina ^a   Vourtsis, Dionussios ^a   Katsoris, Panagiotis ^a   Giannopoulou, Efstathia ^a,d   Courty, Jose ^b   Petrou, Christos ^a   Magafa, Vassiliki ^a   Cordopatis, Paul ^a   Papadimitriou, Evangelia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Université Paris Est Créteil Val de Marne ^*  (France)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

angiogenesis; endothelial cells; migration; nucleolin; pleiotrophin; receptor protein tyrosine phosphatase

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NUCLEOLIN; PLEIOTROPHIN; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR PROTEIN TYROSINE PHOSPHATASE BETA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL NUCLEUS; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; EMBRYO; EMBRYO DEVELOPMENT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84862735049     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-4-422423616     Document Type: Article

References (51)

1. Mikelis C, Koutsioumpa M, Papadimitriou E: Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. Recent Pat Anticancer Drug Discov 2007, 2:175-186.
2. Papadimitriou E, Mikelis C, Lampropoulou E, Koutsioumpa M, Theochari K, Tsirmoula S, Theodoropoulou C, Lamprou M, Sfaelou E, Vourtsis D, Boudouris P: Roles of pleiotrophin in tumor growth and angiogenesis. Eur Cytokine Netw 2009, 20:180-190.
3. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P: HARP induces angiogenesisin viv and in vitr: implication of N or C terminal peptides. Biochem Biophys Res Commun 2001, 282:306-313.
4. Polykratis A, Katsoris P, Courty J, Papadimitriou E: Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem 2005, 280:22454-22461.
5. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, Papadimitriou E: Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J 2009, 23:1459-1469.
6. Westlin WF: Integrins as targets of angiogenesis inhibition. Cancer J 2001, 7(Suppl 3):S139-143.
7. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin avb3 for angiogenesis. Science 1994, 264:569-571.
8. Said EA, Courty J, Svab J, Delbé J, Krust B, Hovanessian AG: Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J 2005, 272:4646-4659.
9. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, Krust B: The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 2000, 261:312-328.
10. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K: Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002, 22:6788-6796.
11. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E: Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 2005, 65:151-158.
12. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S, Papadimitriou E: X-rays modulate extracellular matrixin vivo. Int J Cancer 2001, 94:690-698.
13. Polytarchou C, Gligoris T, Kardamakis D, Kotsaki E, Papadimitriou E: X-rays affect the expression of genes involved in angiogenesis. Anticancer Res 2004, 24:2941-2945.
14. Lee PT, Liao LP, Chang WC, Tseng JT: Epidermal growth factor increases the interaction between nucleolin and heterogeneous nuclear ribonucleoprotein K/poly(C) binding protein 1 complex to regulate the gastrin mRNA turnover. Mol Biol Cell 2007, 18:5004-5013.
15. Nisole S, Krust B, Hovanessian AG: Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res 2002, 276:155-173.
16. Callebaut C, Jacotot E, Krust B, Guichard G, Blanco J, Valenzuela A, Svab J, Muller S, Briand JP, Hovanessian AG: Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein. J Biol Chem 1997, 272:7159-7166.
17. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163:871-878.
18. Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, Luo Y: Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110:2899-2906.
19. Di Segni A, Farin K, Pinkas-Kramarski R: Identification of nucleolin as new ErbB receptors-interacting protein. PLoS One 2008, 3:e2310.
20. Ausprunk DH, Knighton DR, Folkman J: Differentiation of vascular endothelium in the chick chorioallantois: a structural and autoradiographic study. Dev Biol 1974, 38:237-248.
21. Kong Y, Bai PS, Nan KJ, Sun H, Chen NZ, Qi XG: Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int J Colorectal Dis 2012, 27:287-298.
22. Achour A, Laaroubi D, Caruelle D, Barritault D, Courty J: The angiogenic factor heparin affin regulatory peptide (HARP) induces proliferation of human peripheral blood mononuclear cells. Cell Mol Biol (Noisy-le-grand) 2001, 47 Online Pub:OL73-77.
23. Kokolakis G, Mikelis C, Papadimitriou E, Courty J, Karetsou E, Katsoris P: Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells. In Vivo 2006, 20:629-635.
24. Shibuya M: Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001, 33:409-420.
25. Sharifi BG, Zeng Z, Wang L, Song L, Chen H, Qin M, Sierra-Honigmann MR, Wachsmann-Hogiu S, Shah PK: Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:1273-1280.
26. Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, Shalitin D, Zeng Z, Gui D, Perez-Pinera P, Berenson RJ, Said J, Bonavida B, Deuel TF, Berenson JR: Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009, 113:1992-2002.
27. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A: Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001, 276:16772-16779.
28. Souttou B, Ahmad S, Riegel AT, Wellstein A: Signal transduction pathways involved in the mitogenic activity of pleiotrophin. Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. J Biol Chem 1997, 272:19588-19593.
29. Gramage E, Putelli A, Polanco MJ, González-Martín C, Ezquerra L, Alguacil LF, Pérez-Pinera P, Deuel TF, Herradón G: The neurotrophic factor pleiotrophin modulates amphetamine-seeking behaviour and amphetamine-induced neurotoxic effects: evidence from pleiotrophin knockout mice. Addict Biol 2010, 15:403-412.
30. Li J, Wei H, Chesley A, Moon C, Krawczyk M, Volkova M, Ziman B, Margulies KB, Talan M, Crow MT, Boheler KR: The pro-angiogenic cytokine pleiotrophin potentiates cardiomyocyte apoptosis through inhibition of endogenous AKT/PKB activity. J Biol Chem 2007, 282:34984-34993.
31. Re RN, Cook J: An intracrine view of angiogenesis. Bioessays 2006, 28:943-953.
32. Hampton BS, Marshak DR, Burgess WH: Structural and functional characterization of full-length heparin-binding growth associated molecule. Mol Biol Cell 1992, 3:85-93.
33. Take M, Tsutsui JI, Obama H, Ozawa M, Nakayama T, Maruyama I, Arima T, Muramatsu T: Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994, 116:1063-1068.
34. Chang Y, Berenson J, Wang Z, Deuel TF: Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells. Biochem Biophys Res Commun 2006, 351:336-339.
35. Bowden ET, Stoica GE, Wellstein A: Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002, 277:35862-35868.
36. Zhang N, Yeh HJ, Zhong R, Li YS, Deuel TF: A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice. Proc Natl Acad Sci USA 1999, 96:6734-6738.
37. Park TJ, Jeong BR, Tateno C, Kim HS, Ogawa T, Lim IK, Yoshizato K: Pleiotrophin inhibits transforming growth factor beta1-induced apoptosis in hepatoma cell lines. Mol Carcinog 2008, 47:784-796.
38. Soh BS, Song CM, Vallier L, Li P, Choong C, Yeo BH, Lim EH, Pedersen RA, Yang HH, Rao M, Lim B: Pleiotrophin enhances clonal growth and long-term expansion of human embryonic stem cells. Stem Cells 2007, 25:3029-3037.
39. Fogal V, Sugahara KN, Ruoslahti E, Christian S: Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis 2009, 12:91-100.
40. Ishimaru D, Zuraw L, Ramalingam S, Sengupta TK, Bandyopadhyay S, Reuben A, Fernandes DJ, Spicer EK: Mechanism of regulation of bcl-2 mRNA by nucleolin and A + U-rich element-binding factor 1 (AUF1). J Biol Chem 2010, 285:27182-27191.
41. Destouches D, Page N, Hamma-Kourbali Y, Machi V, Chaloin O, Frechault S, Birmpas C, Katsoris P, Beyrath J, Albanese P, Maurer M, Carpentier G, Strub JM, Van Dorsselaer A, Muller S, Bagnard D, Briand JP, Courty J: A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res 2011, 71:3296-3305.
42. Uribe DJ, Guo K, Shin YJ, Sun D: Heterogeneous nuclear ribonucleoprotein K and nucleolin as transcriptional activators of the vascular endothelial growth factor promoter through interaction with secondary DNA structures. Biochemistry 2011, 50:3796-3806.
43. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG: Suppression of tumor growth and angiogenesis by a specific antagonist of the cellsurface expressed nucleolin. PLoS One 2008, 3:e2518.
44. Hoja-Łukowicz D, Przybyło M, Pocheć E, Drabik A, Silberring J, Kremser M, Schadendorf D, Laidler P, Lityńska A: The new face of nucleolin in human melanoma. Canc Immunol Immunother 2009, 58:1471-1480.
45. Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW, Edlund M: Met- Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 2006, 6:197.
46. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y: The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006, 107:3564-3571.
47. Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, Luo Y: Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110:2899-2906.
48. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y: Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 2010, 222:249-260.
49. Watanabe T, Tsuge H, Imagawa T, Kise D, Hirano K, Beppu M, Takahashi A, Yamaguchi K, Fujiki H, Suganuma M: Nucleolin as cell surface receptor for tumor necrosis factor-alpha inducing protein: a carcinogenic factor of Helicobacter pylori. J Cancer Res Clin Oncol 2010, 136:911-921.
50. Mongelard F, Bouvet P: AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther 2010, 12:107-114.
51. Weidle UH, Maisel D, Klostermann S, Schiller C, Weiss EH: Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents. CANCER GENOMICS PROTEOMICS 2011, 8:49-63.